Vijay Mahant received his M.S., Ph.D., and first post-doctorate from LUT (UK). He received his second post-doctorate from the UT Health Science Center at Houston/MD Anderson, TX, USA). Dr. Mahant is a scientist and an entrepreneur with more than 35 years of experience in immuno-and precision medicine (oncology, cardiology, pain management and psychiatry, etc.). His work in diagnostics has included the next generation TSH assay, PSA, Pharmacogenetics, cervical cancer (Human Papilloma Virus) and infectious diseases such as TB and Respiratory Virus Panel (common flu,and a number of coronaviruses) . He held senior positions at Nicholas Institute/ Quest and executive positions at Qualigen and AGI.. He is a founder/co-founder of diagnostic companies such as MediLite. Dr. Manhunt has been involved in fund-raising (about $140 million), Initial Public Offerings (IPOs), including an acquisition. Dr. Mahant is currently the CSO of Oncology Pharma (contract will expire in October 2020). Oncology Pharma is focused on “targeted” chemos and bio-pharmaceutical based drugs “soft biopsies”, including precision oncology combined with artificial intelligence and machine learning. He is a former VP, Precision oncology, Batu Biologics (cellular antiangiogenic vaccine) and in addition, he served on SAB/MAB of Batu Biologics. Dr. Mahant is currently on the advisory board of several young biotech companies such as Trutino BioSciences (an oncology company developing IL-2 based drugs), and Immunicom (a cancer therapeutic device company) , including an oncology hospital (Chipsa) and United Cancer Center (Outpatient clinic, expected to be in operation in summer 2020) Dr. Mahant has 30 issued patents and five patents pending; he has authored and/or co-authored publications in journals and science books; he is the Section Editor for the “Echo System of Translational Medicine, Journal of Translational Medicine.

Professor Adel Ekladious is a senior medical consultant with an extensive experience in general and acute medicine, he is a fellow of few colleges which includes Australia, Glasgow, Ireland, London and America, he worked as a clinical director of medicine and director of physician training. He served in the Panel of the medical Board in Western Australia, his research includes stroke, general neurology, chronic hepatitis, general hepatology, pulmonary hypertension, heart failure and rare diseases.

Dr. Shigeo Masuda received his MD from the University of Tokyo in 1996, and PhD in Hematology/Oncology from the Graduate School of Medicine, University of Tokyo, Japan. He was an Assistant Professor and an Associate Professor at Jichi Medical University, Japan, from 2007 to 2012, and joined RIKEN CDB in 2011. He studied at the Belmonte Lab in the Salk Institute from 2012 to 2014. Currently, he is an Associate Professor of Cardiovascular Surgery in Osaka University, Japan. His interest is regenerative medicine using iPS-derived cells, including molecular targeted therapy for iPS-derived undifferentiated cells to improve safety.

Field of expertise in Molecular Targeted Therapy,Induced Pluripotent Stem Cell and Regenerative Medicine.

Professor Adel Ekladious is a senior medical consultant with an extensive experience in general and acute medicine, he is a fellow of few colleges which includes Australia, Glasgow, Ireland, London and America, he worked as a clinical director of medicine and director of physician training,
He served in the Panel of the medical Board in Western Australia, his research includes stroke, general neurology, chronic hepatitis, general hepatology, pulmonary hypertension, heart failure and rare diseases.

(Sorush Niknamian PhD MRSB FChE FNNECOS FTSCO ANCC, AANP, ACPE, ACHE, ADA CERP APA FMDCSCO) Ph.D. in Cell and Molecular Biology and Oncology and Professor of Cell and Molecular Biology, Oncology and Biological Attacks. He is a Professional Biologist, Senior Research Scientist, Chartered Scientist and Registered Scientist at Violet Cancer Institute (VCI). His Science Council ID is: A-0008833. He is one of United Kingdom and Indiana Cancer Consortium (ICC) certified. He is a Registered Researcher in the U.S. Government's System for Award Management, Registered Scientist at National Center for Biotechnology Information. He is studying Medicine/Military Medicine at Liberty University (LU), Lynchburg, VA, United States of America. He holds Bachelor’s Degree in Mechatronics Engineering, applied Mathematics, Civil Engineering and Management. He is a Member of US Government National Science Foundation, Member of Hera Swiss Volunteers (ID: 198036), Member of US Army American College of Physicians Chapter, Ambassador of American Cancer Society (ACS CAN) and former Ambassador of European Association for Cancer Research (EACR), Active Member of Federal Health Professionals at US Army Forces and Certified Member of American Red Cross and Food Regulatory Affairs Professionals. He is a Board Member and contributor of Weston A Price Foundation co-founded in 1999 by Sally Fallon (Morell) and nutritionist Mary G. Enig. PhD. He Holds Honorary Doctorate of Cancer Biology and Doctor of Science from Violet Cancer Institute. He is preserved and nominated for the preserved as Position Title: DIRECTOR OF MILITARY SUPPORT, Agency: Army National Guard Units. Announcement Number: ID: WA-10507254-AR-19-161. Extra Information: DIRECTOR OF MILITARY SUPPORT located at the WASHINGTON J3 DCSOPS. Professor Sorush Niknamian is an ACP Chapter member in United States Army and Air Force. Active Member of IMRTC-USA (International Management Research and Technology Consortium Research) as Advisor, Referee, Professor at IMRTC-USA (International Management Research and Technology Consortium Panel. He is a Service Member of Modern Military Association of America. Certified Member of World Medical Association with ID: 5c7b154b01602 as a Junior Medical Doctor. He is an Active Member of the National Guard Association of the United States of America (Branch: Army, Rank: Major, State Affiliation: Maryland and Serving Volunteer at the Peace Corps of the United States of America (Ref ID: 10811430) and certified member of The National Bureau of Asian Research. He is a member of Military Officers Association of America (Member Number: 05670401, Rank: Major).

Amgad Mohammed Rabie Hamed Fouda has completed his MSc and Postgraduate studies in Pharmaceutical and Biomedical Sciences at the age of 30 years from the Faculty of Pharmacy, Mansoura University, Egypt. He is one of the most famous and reputed Egyptian and Arab pharmacists, researchers and scientists. His new researches focused on the synthesis, discovery, and development of new drugs and medicines for the most resistant and untreated human diseases. He is the head of pharmacists at the Dikernis General Hospital (Mansoura, Egypt), a premier governmental hospital in Egypt. He has published more than 25 papers in very reputed journals and serving as an Editorial Board Member of great repute.